DK1176963T3 - Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser - Google Patents

Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser

Info

Publication number
DK1176963T3
DK1176963T3 DK00927101T DK00927101T DK1176963T3 DK 1176963 T3 DK1176963 T3 DK 1176963T3 DK 00927101 T DK00927101 T DK 00927101T DK 00927101 T DK00927101 T DK 00927101T DK 1176963 T3 DK1176963 T3 DK 1176963T3
Authority
DK
Denmark
Prior art keywords
dopamine
drugs
manufacture
treatment
receptor antagonists
Prior art date
Application number
DK00927101T
Other languages
Danish (da)
English (en)
Inventor
Dorothea Starck
Hans-Joerg Treiber
Bernd Muehlbauer
Gerhard Gross
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Application granted granted Critical
Publication of DK1176963T3 publication Critical patent/DK1176963T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK00927101T 1999-05-07 2000-04-28 Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser DK1176963T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19922443A DE19922443A1 (de) 1999-05-07 1999-05-07 Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
PCT/EP2000/003865 WO2000067847A2 (de) 1999-05-07 2000-04-28 Verwendung von dopamin-d3-rezeptorliganden zur herstellung von arzneimittel für die behandlung von nierenfunktionsstörungen

Publications (1)

Publication Number Publication Date
DK1176963T3 true DK1176963T3 (da) 2005-04-25

Family

ID=7908194

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00927101T DK1176963T3 (da) 1999-05-07 2000-04-28 Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser

Country Status (19)

Country Link
US (2) US7098214B1 (cs)
EP (1) EP1176963B1 (cs)
JP (3) JP4727822B2 (cs)
KR (2) KR20010112474A (cs)
CN (2) CN101524356A (cs)
AT (1) ATE284693T1 (cs)
AU (1) AU770671B2 (cs)
BR (1) BR0010337A (cs)
CA (1) CA2368823C (cs)
CZ (1) CZ301832B6 (cs)
DE (2) DE19922443A1 (cs)
DK (1) DK1176963T3 (cs)
ES (1) ES2234597T3 (cs)
HU (1) HU228516B1 (cs)
IL (2) IL146232A0 (cs)
NO (1) NO329325B1 (cs)
PT (1) PT1176963E (cs)
WO (1) WO2000067847A2 (cs)
ZA (1) ZA200110044B (cs)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
EP1223932A4 (en) 1999-10-01 2003-01-15 Smithkline Beecham Corp COMPOUNDS AND METHODS
US20020103198A1 (en) * 2000-12-04 2002-08-01 Fliri Anton F.J Acylamino cyclopropane derivatives
MXPA03006843A (es) * 2001-02-16 2003-11-13 Aventis Pharma Inc Derivados heterociclicos novedosos de ureas y su uso como ligandos para receptor d3 de dopamina.
IL157413A0 (en) 2001-02-16 2004-03-28 Aventis Pharmaceuticals Inc Av Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands
CA2438318A1 (en) * 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
DE10109866A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10109867A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
WO2002078697A1 (en) * 2001-03-29 2002-10-10 Smithkline Beecham Corporation Compounds and methods
DE10131543A1 (de) * 2001-06-29 2003-01-16 Abbott Lab Pyrimidinoxyalkylpiperazine und ihre therapeutische Verwendung
HUP0103987A3 (en) * 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
JP2005516604A (ja) 2002-02-04 2005-06-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド １３１、１４８、１９９、１２３０３、１３９０６、１５５１３、１７８２２、３０２、５６７７、１９４、１４３９３、２８０５９、７３６６、１２２１２、１９８１、２６１、１２４１６、２７０、１４１０、１３７、１８７１、１３０５１、１８４７、１８４９、１５４０２、３４０、１０２１７、８３７、１７６１、８９９０または１３２４９分子を用いて血液障害を処置するための方法および組成物
ES2308157T3 (es) * 2003-03-17 2008-12-01 Bayer Healthcare Ag Disgnosticos y tratamientos para enfermedades asociadas con el receptor de la dopamina d3 (drd3).
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
MX2007001530A (es) * 2004-08-09 2007-04-23 Abbott Gmbh & Co Kg Compuestos de 4-piperazinil-pirimidina adecuados para tratar trastornos que responde a la modulacion del receptor dopamina d3.
WO2006040178A1 (en) 2004-10-14 2006-04-20 Abbott Gmbh & Co.Kg Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to madulation of the dopamine d3 receptor
AU2005293698B2 (en) 2004-10-14 2011-12-15 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
US8232426B2 (en) 2004-10-14 2012-07-31 Abbott Gmbh & Co. Kg Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
TWI382013B (zh) 2004-10-14 2013-01-11 Abbott Gmbh & Co Kg 胺基氫茚多巴胺ｄ３受體拮抗劑
EP2004166A2 (en) * 2006-03-31 2008-12-24 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
WO2008016171A1 (en) * 2006-08-04 2008-02-07 Ajinomoto Co., Inc. Prophylactic/therapeutic agent for renal dysfunction
WO2009093471A1 (ja) * 2008-01-25 2009-07-30 Nihon University アポトーシス抑制薬
KR20190028281A (ko) 2017-09-08 2019-03-18 주식회사 엑소코바이오 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 신장 기능 개선 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE628766A (cs) * 1962-12-26
GB1087514A (en) * 1965-04-09 1967-10-18 Hitachi Ltd Arrangement for damping vibration of steam-turbine blades
DE4223921A1 (de) 1992-07-21 1994-01-27 Hartmut Prof Dr Med Oswald Herstellung und Verwendung von Hemmstoffen der DOPA-Decarboxylase sowie von Dopamin-Rezeptor-Antagonisten zur Bekämpfung der fortschreitenden Verschlechterung der Nierenfunktion beim Menschen
DE4425143A1 (de) * 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE19600934A1 (de) * 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen

Also Published As

Publication number Publication date
AU4559100A (en) 2000-11-21
DE50008964D1 (de) 2005-01-20
US20060223793A1 (en) 2006-10-05
IL146232A0 (en) 2002-07-25
CA2368823C (en) 2008-10-21
US8785447B2 (en) 2014-07-22
EP1176963B1 (de) 2004-12-15
JP5897054B2 (ja) 2016-03-30
CZ301832B6 (cs) 2010-07-07
JP2011088941A (ja) 2011-05-06
EP1176963A2 (de) 2002-02-06
NO20015413D0 (no) 2001-11-06
ES2234597T3 (es) 2005-07-01
US7098214B1 (en) 2006-08-29
BR0010337A (pt) 2002-02-13
IL146232A (en) 2007-06-03
KR100781828B1 (ko) 2007-12-03
HUP0202399A3 (en) 2003-02-28
AU770671B2 (en) 2004-02-26
ATE284693T1 (de) 2005-01-15
WO2000067847A3 (de) 2001-08-02
JP2002544178A (ja) 2002-12-24
CN1360502B (zh) 2010-08-04
NO20015413L (no) 2001-11-15
HU228516B1 (en) 2013-03-28
CN101524356A (zh) 2009-09-09
KR20010112474A (ko) 2001-12-20
CN1360502A (zh) 2002-07-24
NO329325B1 (no) 2010-09-27
JP2014098044A (ja) 2014-05-29
ZA200110044B (en) 2003-03-06
CZ20014015A3 (cs) 2002-02-13
KR20070040425A (ko) 2007-04-16
DE19922443A1 (de) 2000-11-09
CA2368823A1 (en) 2000-11-16
WO2000067847A2 (de) 2000-11-16
JP5542713B2 (ja) 2014-07-09
HUP0202399A2 (hu) 2002-12-28
PT1176963E (pt) 2005-05-31
JP4727822B2 (ja) 2011-07-20

Similar Documents

Publication Publication Date Title
DK1176963T3 (da) Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser
BG108491A (en) 5-ht receptor ligands and uses thereof
NO20034122L (no) Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
ATE389404T1 (de) Kappa-opioid-rezeptor-liganden
DE602005015577D1 (de) Harnstoff-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
PA8521501A1 (es) Ligandos para receptores de melanocortina
PT1149078E (pt) Ligandos receptores de 5-ht6 selectivos
DE602004008631D1 (de) Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
ATE346082T1 (de) Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
DK1373256T3 (da) CCR5-antagonister, der er nyttige til behandling af AIDS
DK1200073T3 (da) Selektive iGluR5-receptorantagonister til behandling af migræne
MXPA06000701A (es) Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
DE60332663D1 (de) CCR1-Rezeptor-Antagonisten zur Behandlung u.a. Demyelinisierender entzündlicher Erkrankungen
ATE433966T1 (de) Methylendipiperidinderivate
DE60314896D1 (de) 5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert
DK2001456T3 (da) Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
SI1853232T1 (sl) Stabilna kristalna oblika bifeprunoks-mezilata, njegove dozirne oblike in postopki za njihovo uporabo
MXPA06000700A (es) Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6.
TR200100240T2 (tr) Anksiyete bozukluklarının tedavisi
DE60332769D1 (de) Indole, die sich zur behandlung von mit dem androgenrezeptor in zusammenhang stehenden krankheiten eignen
PT1143942E (pt) Uso de ligandos de receptores gaba para a manufactura de medicamentos para o tratamento de doencas neurodegenerativas
DK1503764T3 (da) 5-HT4-receptor-antagonister til behandling af hjertesvigt